Recently, ctDNA-based NGS analysis indicated that NSCLC patients with high blood TMB (bTMB) receiving anti-PD-L1 antibody atezolizumab on the OAK/POPLAR trials had improved survival compared with bTMB-low patients [22]. Here, CD274 is linked to non-small cell lung carcinoma.